Background

Lewy bodies are pathological hallmarks for the diagnosis of Parkinson’s disease, where the core components are composed of aggregated forms of α-synuclein (α-syn). Although α-syn has been investigated as a potential biomarker for PD, its usage has been limited and still remains controversial.

Objective

An accurate enzyme-linked immunosorbent assay (ELISA) was developed for the detection of α-syn in plasma. The hemolysis score was calculated to eliminate the additive α-syn levels from RBCs. Human plasma samples were collected in heparinized blood tubes from idiopathic Parkinson disease (IPD) and healthy control (HC).

Result

Hemolysis score had a strong correlation with the level of plasma α-syn. From the limited set of samples in this preliminary study, decreased α-syn concentrations were observed in patients with IPD in comparison to HC after adjusting for hemolysis factor. Similar results with a commercial ELISA kit were found for measuring α-syn from the same set of samples with lower correlation and the reduced accuracy of diagnosis than the current study.

Conclusion

The adjustments for the hemolysis factor would be indispensable, supporting plasma α-syn as a potential surrogate biomarker for distinguishing IPD from HC.

中文翻译：

---

调整溶血因子后特发性帕金森病患者血浆α-突触核蛋白降低

背景

路易小体是帕金森氏病诊断的病理标志，其核心成分由聚集形式的α-突触核蛋白（α-syn）组成。尽管已经研究了α-syn作为PD的潜在生物标志物，但其使用受到限制，仍然存在争议。

目的

开发了一种精确的酶联免疫吸附测定（ELISA），用于检测血浆中的α-syn。计算溶血分数以消除RBC中加和的α-syn水平。从特发性帕金森病（IPD）和健康对照（HC）的肝素化血管中收集人血浆样品。

结果

溶血评分与血浆α-syn水平密切相关。在这项初步研究中，从有限的样本集中，在调整溶血因子后，与HC相比，IPD患者的α-syn浓度降低。与目前的研究相比，使用商业化的ELISA试剂盒测量同一组样品中的α-syn具有更低的相关性和更低的诊断准确性，其结果相似。

结论

溶血因子的调整将是必不可少的，支持血浆α-syn作为区分IPD和HC的潜在替代生物标记。